Currently, there are 61.92M common shares owned by the public and among those 57.71M shares have been available to trade.
The company’s stock has a 5-day price change of -6.76% and 8.92% over the past three months. FULC shares are trading 26.67% year to date (YTD), with the 12-month market performance up to 51.33% higher. It has a 12-month low price of $3.14 and touched a high of $13.70 over the same period. FULC has an average intraday trading volume of 911.14K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -5.82%, 5.27%, and 10.28% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Fulcrum Therapeutics Inc (NASDAQ: FULC) shares accounts for 84.26% of the company’s 61.92M shares outstanding.
It has a market capitalization of $533.52M and a beta (3y monthly) value of 2.24. The earnings-per-share (ttm) stands at -$0.35. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.53% over the week and 7.98% over the month.
Analysts forecast that Fulcrum Therapeutics Inc (FULC) will achieve an EPS of -0.41 for the current quarter, -0.43 for the next quarter and -1.43 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.47 while analysts give the company a high EPS estimate of -0.47. Comparatively, EPS for the current quarter was -0.39 a year ago. Earnings per share for the fiscal year are expected to increase by 76.19%, and -263.21% over the next financial year. EPS should grow at an annualized rate of 16.40% over the next five years, compared to 1.09% over the past 5-year period.
Looking at the support for the FULC, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on May 20, 2024, with the firm’s price target at $23. RBC Capital Mkts coverage for the Fulcrum Therapeutics Inc (FULC) stock in a research note released on March 13, 2024 offered a Outperform rating with a price target of $14. Goldman was of a view on September 25, 2023 that the stock is Neutral, while H.C. Wainwright gave the stock Buy rating on August 23, 2023, issuing a price target of $5- $14. Stifel on their part issued Buy rating on August 22, 2023.
